Furthermore, it was reported that this risk increases with the duration of exposure to GLP-1 receptor agonists, with the highest risk observed after 1.6 years
Markets can absorb that, we think, but it creates friction
The appeal of GLP-1 patches is that they claim to achieve prescription weight loss results without the high cost
Along with the injections, individuals are required to make lifestyle changes such as following a healthy diet and engaging in regular exercise
An NIH systematic review on triple agonism-based obesity therapies provides further context, confirming that retatrutides phase 2 dataset remains the most extensive published for any triple agonist to date
Zepbound was shown in clinical trials to yield more than 20% average weight loss on higher doses over 72 weeks, stronger results than seen with other approved medicines